MX2017011598A - Metodos para tratar proteinopatias. - Google Patents
Metodos para tratar proteinopatias.Info
- Publication number
- MX2017011598A MX2017011598A MX2017011598A MX2017011598A MX2017011598A MX 2017011598 A MX2017011598 A MX 2017011598A MX 2017011598 A MX2017011598 A MX 2017011598A MX 2017011598 A MX2017011598 A MX 2017011598A MX 2017011598 A MX2017011598 A MX 2017011598A
- Authority
- MX
- Mexico
- Prior art keywords
- proteinopathy
- subject
- methods
- quinuclidine compound
- administering
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- -1 quinuclidine compound Chemical class 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131071P | 2015-03-10 | 2015-03-10 | |
| PCT/US2016/021512 WO2016145046A1 (en) | 2015-03-10 | 2016-03-09 | Methods for treating proteinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011598A true MX2017011598A (es) | 2017-12-20 |
Family
ID=55587378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011598A MX2017011598A (es) | 2015-03-10 | 2016-03-09 | Metodos para tratar proteinopatias. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20180036295A1 (https=) |
| EP (2) | EP4349408A3 (https=) |
| JP (2) | JP6990110B2 (https=) |
| KR (1) | KR20170123329A (https=) |
| CN (1) | CN107872976A (https=) |
| AU (1) | AU2016229826A1 (https=) |
| CA (1) | CA2978883A1 (https=) |
| EA (1) | EA201791993A1 (https=) |
| ES (1) | ES2973101T3 (https=) |
| HK (1) | HK1244217A1 (https=) |
| HU (1) | HUE065628T2 (https=) |
| IL (1) | IL254393A0 (https=) |
| MX (1) | MX2017011598A (https=) |
| PL (1) | PL3267983T3 (https=) |
| PT (1) | PT3267983T (https=) |
| TW (1) | TW201642855A (https=) |
| WO (1) | WO2016145046A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| KR20200010487A (ko) * | 2017-06-19 | 2020-01-30 | (주) 카이노스메드 | 알파-시누클레인 조절제 |
| TWI644673B (zh) * | 2017-07-27 | 2018-12-21 | 百朗克股份有限公司 | 頭孢曲松的用途 |
| CN113645969A (zh) * | 2019-02-04 | 2021-11-12 | 建新公司 | 用于治疗与溶酶体贮积症相关的症状和病症的方法 |
| CN114040762A (zh) * | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| AU2020384066B2 (en) * | 2019-11-15 | 2025-10-30 | Green Cross Corporation | Novel derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
| JP2023512366A (ja) | 2020-02-03 | 2023-03-27 | ジェンザイム・コーポレーション | リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法 |
| CA3169779A1 (en) | 2020-02-28 | 2021-09-02 | Andrew Mark Griffin | Kcnt1 inhibitors and methods of use |
| WO2021187486A1 (ja) * | 2020-03-17 | 2021-09-23 | 大日本住友製薬株式会社 | オキサジアゾール誘導体 |
| AU2021241530A1 (en) * | 2020-03-23 | 2022-10-20 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| AU2021311131B2 (en) * | 2020-07-24 | 2026-02-19 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| US20230372313A1 (en) * | 2020-07-30 | 2023-11-23 | Genzyme Corporation | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| JP2025541739A (ja) | 2022-12-01 | 2025-12-23 | ジェンザイム・コーポレーション | Ｃｙｐ３ａ４の強力な又は中程度の阻害剤と組み合わせたベングルスタット |
| WO2025262570A1 (en) | 2024-06-17 | 2025-12-26 | Genzyme Corporation | Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683A (en) | 1846-08-08 | waring and richard e | ||
| US195A (en) | 1837-05-15 | Machine fob cutting and dressing stone | ||
| BE640616A (https=) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| KR101987736B1 (ko) * | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | 글루코실세라마이드 합성효소 억제제 |
| CA2840224C (en) * | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
-
2016
- 2016-03-08 TW TW105107080A patent/TW201642855A/zh unknown
- 2016-03-09 PT PT167110881T patent/PT3267983T/pt unknown
- 2016-03-09 CN CN201680026839.XA patent/CN107872976A/zh active Pending
- 2016-03-09 HU HUE16711088A patent/HUE065628T2/hu unknown
- 2016-03-09 HK HK18103748.9A patent/HK1244217A1/zh unknown
- 2016-03-09 WO PCT/US2016/021512 patent/WO2016145046A1/en not_active Ceased
- 2016-03-09 PL PL16711088.1T patent/PL3267983T3/pl unknown
- 2016-03-09 AU AU2016229826A patent/AU2016229826A1/en not_active Abandoned
- 2016-03-09 EP EP23217745.1A patent/EP4349408A3/en active Pending
- 2016-03-09 CA CA2978883A patent/CA2978883A1/en not_active Abandoned
- 2016-03-09 ES ES16711088T patent/ES2973101T3/es active Active
- 2016-03-09 EA EA201791993A patent/EA201791993A1/ru unknown
- 2016-03-09 MX MX2017011598A patent/MX2017011598A/es unknown
- 2016-03-09 KR KR1020177027604A patent/KR20170123329A/ko not_active Withdrawn
- 2016-03-09 JP JP2017547448A patent/JP6990110B2/ja active Active
- 2016-03-09 US US15/556,444 patent/US20180036295A1/en not_active Abandoned
- 2016-03-09 EP EP16711088.1A patent/EP3267983B1/en active Active
-
2017
- 2017-09-10 IL IL254393A patent/IL254393A0/en unknown
-
2020
- 2020-03-02 US US16/807,102 patent/US20200197374A1/en active Pending
-
2021
- 2021-05-06 JP JP2021078459A patent/JP7374149B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3267983T3 (pl) | 2024-05-13 |
| CN107872976A (zh) | 2018-04-03 |
| US20200197374A1 (en) | 2020-06-25 |
| HUE065628T2 (hu) | 2024-06-28 |
| WO2016145046A1 (en) | 2016-09-15 |
| ES2973101T3 (es) | 2024-06-18 |
| US20180036295A1 (en) | 2018-02-08 |
| JP2021119185A (ja) | 2021-08-12 |
| IL254393A0 (en) | 2017-11-30 |
| CA2978883A1 (en) | 2016-09-15 |
| JP6990110B2 (ja) | 2022-02-10 |
| HK1244217A1 (zh) | 2018-08-03 |
| EP3267983B1 (en) | 2023-12-20 |
| PT3267983T (pt) | 2024-03-12 |
| JP7374149B2 (ja) | 2023-11-06 |
| JP2018507886A (ja) | 2018-03-22 |
| AU2016229826A1 (en) | 2017-10-26 |
| EP3267983A1 (en) | 2018-01-17 |
| EA201791993A1 (ru) | 2017-12-29 |
| KR20170123329A (ko) | 2017-11-07 |
| EP4349408A3 (en) | 2024-06-19 |
| TW201642855A (zh) | 2016-12-16 |
| EP4349408A2 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011598A (es) | Metodos para tratar proteinopatias. | |
| PT3873604T (pt) | Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina | |
| MX2023009483A (es) | Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia. | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
| PH12016502095A1 (en) | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| SI3805233T1 (sl) | (r)in (s) enantiomera n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo(4,5-b)piridin-6-il) -2-(2-metilpiridin-4-il)oksazol-karboksamid kot inhibitorji irak4 za zdravljenje raka | |
| BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
| WO2014160871A3 (en) | Methods and agents for treating alzheimer's disease | |
| UA118209C2 (uk) | Гетероариламіди як інгібітори агрегації білків | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| BR112015001096A2 (pt) | derivados de di e tri-heteroaril como inibidores de agregação de proteína | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| SG10202009001TA (en) | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| ES3064246T3 (en) | Compounds for use in methods for treating alzheimer's disease | |
| MX2016008968A (es) | Compuestos organicos. | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| EP3634979A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS | |
| HK40053333A (en) | Methods for treating parkinson's disease by administering resiniferatoxin | |
| GB201911821D0 (en) | Compounds for use in the treatment of liver disease | |
| AU2018904309A0 (en) | Treatment of alzheimer's disease with augmenter of liver regeneration |